Non-metastatic muscle-invasive bladder cancer: the role of age in receiving treatment with curative intent

被引:5
|
作者
van Hoogstraten, Lisa M. C. [1 ,2 ]
Witjes, J. Alfred [3 ]
Meijer, Richard P. [4 ]
Ripping, Theodora M. [1 ]
Kiemeney, Lambertus A. [2 ,3 ]
Aben, Katja K. H. [1 ,2 ]
机构
[1] Netherlands Comprehens Canc Org, POB 1281, NL-6501 BG Utrecht, Netherlands
[2] Radboud Univ Nijmegen Med Ctr, Radboud Inst Hlth Sci, Nijmegen, Netherlands
[3] Radboud Univ Nijmegen Med Ctr, Dept Urol, Nijmegen, Netherlands
[4] Univ Med Ctr Utrecht, Dept Oncol Urol, Utrecht, Netherlands
关键词
muscle-invasive bladder cancer (MIBC); patient and tumour characteristics; survival; treatment; urothelial bladder carcinoma; variation in healthcare; #BladderCancer; #blcsm; LONG-TERM OUTCOMES; RADICAL CYSTECTOMY; MODALITY THERAPY; PRESERVATION; CHEMOTHERAPY; PATTERNS; SCORE;
D O I
10.1111/bju.15697
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives To evaluate which patient and tumour characteristics are associated with remaining untreated in patients with potentially curable, non-metastatic muscle-invasive bladder cancer (MIBC), and to compare survival of untreated vs treated patients with similar characteristics. Patients and methods For this cohort study, 15 047 patients diagnosed with cT2-T4aN0/xM0/x urothelial MIBC between 2005 and 2019 were identified in the Netherlands Cancer Registry. Factors associated with remaining untreated were identified using logistic regression analyses. Interhospital variation was assessed using multilevel analysis. Using a propensity score, the median overall survival (mOS) of untreated and treated patients was evaluated. Analyses were stratified by age (<75 vs >= 75 years). Results One-third of patients aged >= 75 years remained untreated; increasing age, worse performance status, worse renal function, cT4a stage and previous radiotherapy in the abdomen/pelvic area increased the odds of remaining untreated. One in 10 patients aged <75 years remained untreated; significant associations were only found for performance status, renal function and cT4a stage. Interhospital variation for remaining untreated was largest for patients aged >= 75 years, ranging from 37% to 69% (case-mix-adjusted). Irrespective of age, mOS was significantly worse for untreated patients: 6.4 months (95% confidence interval [CI] 5.1-7.3) vs 16.0 months (95% CI 13.5-19.1) for treated patients. Conclusion On average, one in five patients with non-metastatic MIBC remained untreated. Untreated patients were generally older and had a more unfavourable prognostic profile. Untreated patients had significantly worse overall survival, regardless of age. Age alone should therefore not affect treatment decision-making. Considering the large interhospital variation, a proportion of untreated patients might be wrongfully denied life-prolonging treatment.
引用
收藏
页码:764 / 775
页数:12
相关论文
共 50 条
  • [1] Usefulness of neoadjuvant chemotherapy in non-metastatic muscle-invasive bladder cancer
    Esper Rueda, J. A.
    Carrion Lopez, P.
    Donate Moreno, M. J.
    Herais Raya, L.
    Sanchez Migallon, I. Diaz de Mera
    Legido Gomez, O.
    Rico Marco, S.
    Martinez Ruiz, J.
    Nogueron Martinez, E.
    Salinas Sanchez, A. S.
    ACTAS UROLOGICAS ESPANOLAS, 2021, 45 (04): : 300 - 308
  • [2] Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline
    Chang, Sam S.
    Bochner, Bernard H.
    Chou, Roger
    Dreicer, Robert
    Kamat, Ashish M.
    Lerner, Seth P.
    Lotan, Yair
    Meeks, Joshua J.
    Michalski, Jeff M.
    Morgan, Todd M.
    Quale, Diane Z.
    Rosenberg, Jonathan E.
    Zietman, Anthony L.
    Holzbeierlein, Jeffrey M.
    JOURNAL OF UROLOGY, 2017, 198 (03): : 552 - 559
  • [3] Perioperative chemotherapy and immunotherapy to optimize cystectomy outcomes in the curative intent of non-metastatic muscle-invasive bladder cancer: A systematic review and meta-analysis
    Boutaleb, Ismail
    Mjaess, Georges
    Roumeguere, Thierry
    FRENCH JOURNAL OF UROLOGY, 2024, 34 (09):
  • [4] Identifying care fragmentation in the management of non-metastatic muscle-invasive bladder cancer
    Bhattacharya, Manisha
    Sun, Zhaojun
    Jacobs, Bruce Lee
    Yabes, Jonathan G.
    Sabik, Lindsay M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] Selective bladder preservation with curative intent for muscle-invasive bladder cancer: A contemporary review
    Koga, Fumitaka
    Kihara, Kazunori
    INTERNATIONAL JOURNAL OF UROLOGY, 2012, 19 (05) : 388 - 401
  • [6] The promise and challenges of neoadjuvant immunotherapy in the management of non-metastatic muscle-invasive bladder cancer
    Janisch, Florian
    Rink, Michael
    Shariat, Shahrokh F.
    BJU INTERNATIONAL, 2020, 125 (06) : 753 - 755
  • [7] MANAGING PATIENTS WITH NON-METASTATIC MUSCLE-INVASIVE BLADDER CANCER - A SURVEY OF CLINICIAN PRACTICE
    Long, A.
    Sengupta, S.
    Stockler, M.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 : 61 - 61
  • [8] Bladder preservation in non-metastatic muscle-invasive bladder cancer (MIBC): a single-institution experience
    Gerardi, Marianna A.
    Jereczek-Fossa, Barbara A.
    Zerini, Dario
    Surgo, Alessia
    Dicuonzo, Samantha
    Spoto, Ruggero
    Fodor, Cristiana
    Verri, Elena
    Rocca, Maria Cossu
    Nole, Franco
    Muto, Matteo
    Ferro, Matteo
    Musi, Gennaro
    Bottero, Danilo
    Matei, Deliu V.
    De Cobelli, Ottavio
    Orecchia, Roberto
    ECANCERMEDICALSCIENCE, 2016, 10
  • [9] BLADDER PRESERVATION IN NON-METASTATIC MUSCLE-INVASIVE BLADDER CANCER (MIBC): A SINGLE-INSTITUTION EXPERIENCE
    Gerardi, Marianna
    Jereczek, Barbara Alicja
    Zerini, Dario
    Surgo, Alessia
    Dicuonzo, Samantha
    Spoto, Ruggero
    Fodor, Cristiana
    Verri, Elena
    Rocca, Maria Cossu
    Nole, Franco
    Muto, Matteo
    Ferro, Matteo
    Musi, Gennaro
    Bottero, Danilo
    Matei, Deliu Victor
    De Cobelli, Ottavio
    Orecchia, Roberto
    ANTICANCER RESEARCH, 2017, 37 (04) : 2131 - 2131
  • [10] Survival after curative treatment of muscle-invasive bladder cancer
    Fossa, SD
    Aass, N
    Ous, S
    Waehre, H
    Ilner, K
    Hannisdal, E
    ACTA ONCOLOGICA, 1996, 35 : 59 - 65